EN DE
Watch Tecan Group AG for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Tecan Group AG (TECN) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Tecan Group AG stock CHF 98.60, price CHF 258, that is 61.7% below the price, quality 60 out of 100. Rating: strongly overvalued. Calculated from audited financials with 13 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare CH · ISIN CH0012100191

TG Tecan Group AG logo Thin data Nov 8, 2026

Tecan Group AG

TECN · SW
Solid, but very expensive

Our calculation puts a fair price 62% below what the stock costs today.

Quality 60/100
Low debt
Generates free cash flow
1.2% dividend yield · Cash covered
Fair value CHF 98.60 · Strongly overvalued
Weak Growth (revenue 3y −8.3 %/yr in CHF)
Loss-making · -13.4% net margin (TTM)
Trails peers (1/14)
Narrow moat 21/100 · thin data
Thin data
Watch Tecan Group AG for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

CHF 574.26 CHF 113.47 Fair Value CHF 98.60 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.

How to read this chart

60‑month range CHF 113.47 – CHF 574.26 · fair‑value band CHF 72.41 – CHF 124.78 · the CHF 257.60 price screens above the CHF 98.60 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.

Follow Tecan Group in your weekly email

Every Wednesday you see whether Tecan Group is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Tecan Group AG provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally. It operates in two segments: Life Sciences Business and Partnering Business.

Show moreShow less

The company offers liquid handling and automation, microplate readers and washers, software, consumables, sequencing reagents, immunoassays and antibodies, and Tecan Labwerx, an end-to-end automation solution. It also provides PARAMIT, a contract design and manufacturing service.

Tecan Group AG has a strategic collaboration with NVIDIA Corporation to develop AI-enabled platform for data-driven laboratories to help discoveries and lab productivity. The company was founded in 1980 and is headquartered in Männedorf, Switzerland.

Stock analysis

Tecan Group AG (TECN) currently trades at CHF 257.60, while our model-based Fair Value estimate is CHF 98.60, 62% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of CHF 128.91 per share, and 0 of the 13 models we run sit above the CHF 257.60 price.

Bear case: the Asset-Based group reads lowest at CHF 13.40, and 13 of the 13 models stay below the price. Data coverage for this calculation is low.

Scenario range: CHF 72.41 (bear) to CHF 124.78 (bull), the price of CHF 257.60 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 60/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Tecan Group AG reported revenue of CHF 882M in FY2025 versus CHF 947M in FY2021, a compound −1.7%/yr. Reported net income was −CHF 111M in FY2025.

Key figures

Market cap CHF 3.2B Mid · P/S ratio 3.47 · EPS (TTM) CHF −9.16 · Dividend yield 1.2% · Net margin −13.4% · Return on equity −9.7% · Return on assets (EBIT) 5.3% (5-year average) · Operating margin 4.8%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 21 out of 100 (low confidence).

What moves the price

The share trades about 2% below its 52-week high and 127% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −44% fair-value upside, at −62%, TECN screens richer than that median.

Fair Value models

Bear CHF 72.41 Fair Value CHF 98.60 Bull CHF 124.78
Price CHF 257.60 · Downside -61.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF CHF 97.18 CHF 144.40 CHF 212.36 78
Growth DCF CHF 98.75 CHF 140.72 CHF 197.64 76
EPV CHF 26.26 CHF 30.07 CHF 33.35 74
All 13 models by family
DCF Models
FCF DCF CHF 97.18 CHF 144.40 CHF 212.36 78
5Y Revenue Exit CHF 55.61 CHF 75.36 CHF 99.07 71
5Y EBITDA Exit CHF 86.24 CHF 131.97 CHF 184.19 73
10Y Revenue Exit CHF 69.57 CHF 90.76 CHF 116.67 66
10Y EBITDA Exit CHF 89.44 CHF 128.91 CHF 179.44 66
Earnings-Based
EPV CHF 26.26 CHF 30.07 CHF 33.35 74
Multiples
EV/EBIT CHF 40.23 CHF 54.78 CHF 69.32 66
EV/EBITDA CHF 84.51 CHF 113.81 CHF 143.11 67
EV/Revenue CHF 27.74 CHF 41.09 CHF 54.44 53
Asset-Based
NCAV (Graham) CHF 8.85 CHF 13.40 CHF 16.75 54
Growth DCF
Growth DCF CHF 98.75 CHF 140.72 CHF 197.64 76
Rev-Margin DCF CHF 55.61 CHF 76.77 CHF 101.27 71
Economic Profit
ROIC Compounder CHF 26.26 CHF 30.07 CHF 33.35 70

The fair value above starts from this blend and is adjusted for a year distorted by one-off effects.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 60/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 13
How much profit the company makes from its sales and capital
Quality Growth 30
Are margins and returns getting better?
Cashflow 60
Do the profits arrive as real cash?
Financial strength 86
Debt, balance sheet and risk of trouble
Investment 96
Does it invest with discipline instead of growing at any price?
Low Volatility 53
How calm the share price moves, does not count
Price momentum 100
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 99
Distance to the 52-week high, does not count
New shares 97
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 37/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−5.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−8.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.8%
Start year 2020 (pandemic). Over 10 years: +7.2% a year
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
16.8% (2020) → 4.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+16.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+4.1%
Yearly sales growth analysts expect, extended to five years.
After inflation (Switzerland: IMF forecast 0.6% a year to 2030, 0.8% from 2016 to 2025) that is about +15.6% a year for the price and +3.5% for the forecasts.
Forecast 2026 (sales)+0.7%
Forecast 2027 (sales)+5.7%
Projected 2028 (sales)+5.2%
Projected 2029 (sales)+4.8%
Projected 2030 (sales)+4.3%

TECN screens overvalued: fair value 62% below the price. Compare with Intuitive Surgical, Inc →

Note from the team Oct 11, 2026
AI conclusion: Laboratory automation and OEM precision instruments form the core strength, while limited evidence of a durable moat and negative net income despite positive cash flow represent the key weakness.
Main risk: Integration and market risks tied to the Rewired program could limit sustained margin expansion in laboratory automation and diagnostics.
Tecan builds its business around laboratory automation and OEM supply of precision instruments for life sciences and diagnostics. The Rewired transformation program targets efficiency gains to support the shift into AI-enabled labs, following first-half local-currency growth of 3.4 percent and a slightly higher adjusted EBITDA margin. Does the program deliver sustained margin expansion that outweighs modest reported sales pressure, or do integration and market risks limit the upside?
Join the discussion →

Compare Tecan Group AG with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 181 stocks

Beats the industry median on 1/13 measures
Overall it trails its industry peers.
Valuation
Quality Score 60 · Above median
Fair Value upside −61.7% · Bottom 25%
Profitability
Return on assets −6.5% · Bottom 25%
Net margin (12 months) −13.4% · Bottom 25%
Operating margin (12 months) 4.8% · Below median
Growth and dividend
Revenue growth (quarter YoY) −2.7% · Bottom 25%
Dividend yield (12 months) 1.2% · Below median
Balance sheet
Debt / equity 0.13× · Above median

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/B 2.77× · Pricier than median
P/S (12 months) 3.67× · Pricier than median
Price / free cash flow (fiscal year) 31.1× · Pricier than median
EV/EBITDA 41.6× · Priciest 25%
PEG 1.71× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 25
FUTURE (revenue growth)0 · sector 40
PAST (return on equity)0 · sector 30
HEALTH (low debt)93 · sector 96
DIVIDEND (yield)23 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Solventum Corporation SOLV $90.38 $131.27 +45% vs TECN
EssilorLuxottica Société anonyme EL €193.80 €196.22 +1% vs TECN
Intuitive Surgical, Inc ISRG $452.80 $353.90 −22% vs TECN
Medline Inc MDLN $39.64 $28.59 −28% vs TECN
Alcon Inc ALC CHF 61.30 CHF 34.06 −44% vs TECN
Becton, Dickinson and Company BDX $211.88 $97.80 −54% vs TECN
Straumann Holding STMN CHF 104.50 CHF 45.50 −56% vs TECN
West Pharmaceutical Services, Inc WST $399.81 $139.22 −65% vs TECN
Sartorius Stedim Biotech S.A DIM €225.80 €54.82 −76% vs TECN
Sartorius Aktiengesellschaft SRT €227.00 €42.50 −81% vs TECN

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Tecan Group AG: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Tecan Group AG Fair Value". https://www.fairvalue-calculator.com/stock/TECN

Frequently asked questions

Is Tecan Group AG (TECN) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of CHF 98.60 versus a price of CHF 257.60, about 62% lower (overvalued).
What is the fair value of TECN?
Our model-based fair value for Tecan Group AG is CHF 98.60 (as of Nov 8, 2026), built from audited fundamentals. The current price: CHF 257.60.
What is the quality score of TECN?
Tecan Group AG has a Quality Score of 60/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Tecan Group AG (TECN)?
Our model-based price target is the fair value of CHF 98.60 (as of Nov 8, 2026) from 13 valuation models. Cautious scenario CHF 72.41, optimistic scenario CHF 124.78. It is a calculation from audited fundamentals, not an analyst target.
What is the Tecan Group AG stock forecast for 2026?
Our models put fair value at CHF 98.60, about 62% lower versus a price of CHF 257.60 (overvalued). Cautious scenario CHF 72.41, optimistic scenario CHF 124.78. The calculation is refreshed regularly with new filings.
What is the revenue of Tecan Group AG (TECN)?
Tecan Group AG reported trailing-twelve-month revenue of about CHF 871M (latest available figure, as of Nov 8, 2026).
Does Tecan Group AG pay a dividend?
Tecan Group AG currently shows a dividend yield of 1.16% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of Tecan Group AG (TECN) and when is the ex-dividend date?
Tecan Group AG pays a dividend of CHF 3.00 per share a year, a dividend yield of 1.2%. The last ex-dividend date was Apr 17, 2026. A dividend has been paid every year since at least 1997. Free cash flow covers the dividend 2.78 times. Our assessment: Cash covered. The dividend is fully funded by free cash flow. The payout ratio on earnings is not available for this company.
What growth is priced into Tecan Group AG (TECN)?
For today's price to be fair in a discounted-cash-flow model, Tecan Group AG would have to grow free cash flow by +16.3 % per year for five years (discount rate 9.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +3.8 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of TECN use?
Our models discount Tecan Group AG at 9.5 %: a base by market capitalisation (mid), damped by beta 1.01, country premium for Switzerland. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Tecan Group AG that is +16.3 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.5 %) and the same formula as our fair value.
How much growth has Tecan Group AG (TECN) delivered so far?
Over the past 5 years revenue at Tecan Group AG grew +3.8 % a year. The price currently implies free-cash-flow growth of +16.3 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Tecan Group AG (TECN) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Tecan Group AG (+16.3 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Tecan Group AG (TECN)?
The free-cash-flow yield on the price is 3.22 %: that much free cash flow Tecan Group AG produces per unit of market value. When it exceeds the discount rate of our models (9.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Tecan Group AG (TECN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Tecan Group AG it is CHF 98.60 per share (as of Nov 8, 2026), against a price of CHF 257.60. It is the blended result of 13 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit).
Is Tecan Group AG stock overvalued or undervalued in 2026?
As of Nov 8, 2026, TECN trades above its calculated fair value: price CHF 257.60, fair value CHF 98.60, a gap of about −62% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of TECN?
No. The price is what the market pays today (CHF 257.60); the fair value is what the company's own numbers justify (CHF 98.60). For Tecan Group AG the two are CHF 159.00 per share apart. That gap is exactly why we show both numbers side by side.
How much is Tecan Group AG worth?
The market values Tecan Group AG at about CHF 3.2B (market capitalisation, as of Nov 8, 2026). Per share that is CHF 257.60; our models calculate a fair value of CHF 98.60 per share.
What do the bullish and bearish scenarios say about TECN?
Our models span a range for Tecan Group AG: cautious scenario CHF 72.41, base CHF 98.60, optimistic CHF 124.78 per share (as of Nov 8, 2026, price CHF 257.60). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of TECN?
The PEG ratio of Tecan Group AG is 1.71 (P/E divided by earnings growth, as of Nov 8, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Tecan Group AG (TECN)?
Balance-sheet figures for Tecan Group AG (as of Nov 8, 2026): return on equity −9.7%, debt of 0.13 per unit of equity. They feed the Quality Score of 60/100, which measures business quality independently of the share price.
How far is TECN from its 52-week high?
Tecan Group AG trades at CHF 257.60, about 2% below its 52-week high of CHF 262.00 and 127% above the low of CHF 113.47 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of CHF 98.60 is for.
Which stocks are comparable to Tecan Group AG?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Tecan Group AG stock attractive at the current price?
The data as of Nov 8, 2026: price CHF 257.60, calculated fair value CHF 98.60 (−62%), Quality Score 60/100, from 13 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of TECN calculated?
We run Tecan Group AG through 13 models from 6 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit. Every model gets the same audited fundamentals; the fair value of CHF 98.60 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Tecan Group AG itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Tecan Group AG (TECN)?
The closing price on Nov 6, 2026 was CHF 257.60. Our model-based fair value is CHF 98.60, about 62% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Tecan Group AG right now?
The price sits above even our optimistic bull case (CHF 124.78). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (60/100) and above fair value, neither a clear bargain nor a standout compounder.
Where does the earnings growth of Tecan Group AG (TECN) come from?
Earnings per share at Tecan Group AG grew +7.0 % a year from 2014 to 2025. Broken into its drivers: revenue per share +8.6 %, EBIT margin −3.6 %, tax rate +1.3 %, residual (interest, one-offs) +0.8 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Tecan Group AG

How large is the market capitalisation of Tecan Group AG (TECN)?
The market capitalisation of Tecan Group AG is CHF 3.2B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Tecan Group AG (TECN)?
The price-to-sales ratio of Tecan Group AG is 3.47 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Tecan Group AG (TECN)?
Earnings per share at Tecan Group AG are CHF −9.16. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Tecan Group AG (TECN)?
The dividend yield of Tecan Group AG is 1.2%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Tecan Group AG (TECN)?
The net margin of Tecan Group AG is −13.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Tecan Group AG (TECN)?
The return on equity (ROE) of Tecan Group AG is −9.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Tecan Group AG (TECN)?
On an EBIT basis the return on assets of Tecan Group AG is 5.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Tecan Group AG (TECN)?
The operating margin of Tecan Group AG is 4.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Tecan Group AG (TECN)?
Revenue at Tecan Group AG is growing −2.7% versus a year earlier (3y avg −8.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Tecan Group AG (TECN)?
Earnings per share at Tecan Group AG are growing −29.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Tecan Group AG (TECN) carry?
The net debt of Tecan Group AG is CHF 42.0M (fiscal year 2025, ≈ 0.4 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Tecan Group AG in the live analysis

One click puts Tecan Group AG on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.